Market Madness Showdown: Abbott vs. Novo Nordisk

In honor of March Madness, the Motley Fool's health-care team assembled their own bracket consisting of the 16 largest and best pharmaceutical and biotech stocks on the market. The series kicks off with a tough match up between Abbott , the medical device giant that recently spun-off its pharmaceutical division, and diabetes giant Novo Nordisk . To learn the bull and bear cases for each stock -- and to see which stock will move on to the Elite Eight -- watch the video below.

Abbott Labs has changed forever after losing its branded pharmaceutical business to a spinoff. If you're a current investor, or might be buying shares soon, make sure you truly understand the stock by reading The Motley Fool's brand new premium report on Abbott Labs. The report outlines all of the must-know opportunities and risks, along with a full year of analyst updates to keep you up to speed. Best of all, you can claim this report today by clicking here now.

The article Market Madness Showdown: Abbott vs. Novo Nordisk originally appeared on Fool.com.

Brenton Flynn has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.